Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
暂无分享,去创建一个
J. Radich | J Wagner | R. Storb | B. Sandmaier | D. Maloney | F. Appelbaum | D. Niederwieser | U. Hegenbart | M. Flowers | P. Mcsweeney | H. Kiem | T. Gooley | E. Bryant | C. Yu | R. Nash | F. Grumet | W. Bensinger | B. Torok-Storb | J. Shizuru | G. Georges | K. Blume | T. Chauncey | J. Wagner | M. Flowers | H. Kiem | Cong Yu | J. Radich | A. Molina | S. Minor | C. Yu | C. Yu | Steven Minor
[1] A. Nademanee,et al. Solid cancers after bone marrow transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Jane L. Liesveld,et al. Handbook of Bone Marrow Transplantation , 2000 .
[3] R. Storb,et al. Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis. , 1999, Blood.
[4] N. Young,et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.
[5] H. Deeg,et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. , 1999, Blood.
[6] I. Bernstein,et al. Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome , 1999 .
[7] R. Storb,et al. Mixed chimerism: preclinical studies and clinical applications. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] J. Connors,et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] I. Bernstein,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate , 2017 .
[10] S. Saidman,et al. Mixed lymphohaemopoietic chimerism and graft-ver suslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation , 1999, The Lancet.
[11] R. Verdijk,et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. , 1999, Blood.
[12] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[13] I. Bernstein,et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. , 1999, Blood.
[14] A. Nademanee,et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.
[15] N. Ueno,et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] H. Deeg,et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. , 1998, Blood.
[17] E. Warren,et al. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. , 1998, Blood.
[18] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.
[19] F. Benvenuto,et al. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. , 1998, Haematologica.
[20] A. Nademanee,et al. Phase III Study Comparing Methotrexate and Tacrolimus ( Prograf , FK 506 ) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation , 1998 .
[21] E. Estey,et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.
[22] H. Deeg,et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.
[23] Robert H. Collins,et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Boeckh,et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. , 1996, Blood.
[25] M. Stovall,et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] H. Kantarjian,et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1995, Blood.
[27] J. Radich,et al. Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT. , 1995, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[28] A Ferrant,et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.
[29] S. Mackinnon,et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.
[30] M. Levenstein,et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.
[31] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[32] E Cardis,et al. Effects of low doses and low dose rates of external ionizing radiation: cancer mortality among nuclear industry workers in three countries. , 1995, Radiation research.
[33] J. Radich,et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. , 1995, Blood.
[34] V. Zagonel,et al. Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non‐Hodgkin's lymphomas. A 9‐year experience at a single institution , 1994, Cancer.
[35] H. Deeg,et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. , 1994, Blood.
[36] D. Preston,et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. , 1994, Radiation research.
[37] V. Grégoire,et al. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. , 1994, Cancer research.
[38] D. Porter,et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. , 1994, The New England journal of medicine.
[39] H. Deeg,et al. Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. , 1993, International journal of radiation oncology, biology, physics.
[40] H. Deeg,et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. , 1992, Blood.
[41] M. Boeckh,et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. , 1992, Blood.
[42] A. Rimm,et al. T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.
[43] K. Sullivan,et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.
[44] R. Storb,et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. , 1990, Blood.
[45] M. Pepe,et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants ? , 1990 .
[46] A. Rimm,et al. Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.
[47] K. Sullivan,et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. , 1990, Blood.
[48] W. Wilmanns,et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.
[49] M. Pepe,et al. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. , 1989, Blood.
[50] R Storb,et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.
[51] N. Mendenhall,et al. Total body irradiation for stage II-IV non-Hodgkin's lymphoma: ten-year follow-up. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] K. Sullivan,et al. Bacterial, Fungal, and Protozoan Infection After Marrow Transplantation , 1988 .
[53] A. Butturini,et al. Graft-versus-leukemia following bone marrow transplantation. , 1987, Bone marrow transplantation.
[54] A I Goldman,et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] A I Goldman,et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. , 1987, The New England journal of medicine.
[56] H. Deeg,et al. Marrow graft rejection and veno-occlusive disease of the liver in patients with aplastic anemia conditioned with cyclophosphamide and cyclosporine. , 1986, Transplantation.
[57] K. Sullivan,et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.
[58] R. Storb,et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.
[59] R Storb,et al. Bone-marrow transplantation (second of two parts). , 1975, The New England journal of medicine.
[60] R Storb,et al. Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.
[61] J. Burchenal,et al. Effect of total-body irradiation on the transplantability of mouse leukemias. , 1960, Cancer research.